Background: Despite the fact that thiocolchicoside has been widely used in the treatment of musculoskeletal pain, its efficacy has never been systematically evaluated. We carried out a systematic review and meta-analysis of randomized clinical trials (RCTs) to appraise the existing evidence on the efficacy of thiocolchicoside for musculoskeletal pain management. Methods: The literature search was performed on multiple databases, extracting reports of RCTs evaluating the efficacy of thiocolchicoside compared to placebo or no exposure. The reduction in pain intensity was evaluated through between-groups mean differences (MDs) in Visual Analogue Scale (VAS) scores after the intervention. The pooled effect estimates were compared to a minimally important difference (MID) of 1 point on a scale from 0 to 10. Results: We retrieved eight RCTs, including a total of 1397 patients. All the included studies were determined as being at high risk of bias. Seven trials evaluated patients with acute low back pain. After 2–3 days of treatment, the pooled MD in VAS score was −0.49 (95%CI = −0.90; −0.09) compared to controls. After 5–7 days of treatment, the summary MD was −0.82 (95%CI = −1.46; −0.18). Conclusions: Although thiocolchicoside was found to significantly reduce patient-reported low back pain, the clinical impact was very small, as the pooled effect estimates were below the MID, and the overall certainty of evidence was very low. In light of the safety concerns raised by the European Medicine Agency, an in-depth analysis on the risk–benefit balance of thiocolchicoside is required.
Bianconi, A., Fiore, M., Rosso, A., Acuti Martellucci, C., Calò, G.L., Cioni, G., et al. (2024). Efficacy of Thiocolchicoside for Musculoskeletal Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. JOURNAL OF CLINICAL MEDICINE, 13(20), 1-10 [10.3390/jcm13206133].
Efficacy of Thiocolchicoside for Musculoskeletal Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Bianconi, Alessandro;Fiore, Matteo;Rosso, Annalisa;Acuti Martellucci, Cecilia;Imperiali, Gianmarco;
2024
Abstract
Background: Despite the fact that thiocolchicoside has been widely used in the treatment of musculoskeletal pain, its efficacy has never been systematically evaluated. We carried out a systematic review and meta-analysis of randomized clinical trials (RCTs) to appraise the existing evidence on the efficacy of thiocolchicoside for musculoskeletal pain management. Methods: The literature search was performed on multiple databases, extracting reports of RCTs evaluating the efficacy of thiocolchicoside compared to placebo or no exposure. The reduction in pain intensity was evaluated through between-groups mean differences (MDs) in Visual Analogue Scale (VAS) scores after the intervention. The pooled effect estimates were compared to a minimally important difference (MID) of 1 point on a scale from 0 to 10. Results: We retrieved eight RCTs, including a total of 1397 patients. All the included studies were determined as being at high risk of bias. Seven trials evaluated patients with acute low back pain. After 2–3 days of treatment, the pooled MD in VAS score was −0.49 (95%CI = −0.90; −0.09) compared to controls. After 5–7 days of treatment, the summary MD was −0.82 (95%CI = −1.46; −0.18). Conclusions: Although thiocolchicoside was found to significantly reduce patient-reported low back pain, the clinical impact was very small, as the pooled effect estimates were below the MID, and the overall certainty of evidence was very low. In light of the safety concerns raised by the European Medicine Agency, an in-depth analysis on the risk–benefit balance of thiocolchicoside is required.File | Dimensione | Formato | |
---|---|---|---|
jcm-13-06133-s001.zip
accesso aperto
Descrizione: , Figure S1: Sensitivity analysis excluding results derived by topical administration from the thiocolchicoside efficacy on VAS scores at 2–3 days time-point meta-analysis; Figure S2: Sensitivity analysis excluding results derived by topical administration from the thiocolchicoside efficacy on VAS scores at 5–7 days time-point meta-analysis; Figure S3: Sensitivity analysis excluding results derived by oral administration from the thiocolchicoside efficacy on VAS scores at 2–3 days time-point meta-analysis; Figure S4: Sensitivity analysis excluding results derived by oral administration from the thiocolchicoside efficacy on VAS scores at 5–7 days time-point meta-analysis; Figure S5: Sensitivity analysis excluding imputed results from Aksoy 2002 from the thiocolchicoside efficacy on VAS scores at 5–7 days time-point meta-analysis; Figure S6: Sensitivity analysis excluding imputed results from Desai 2011 from the thiocolchicoside efficacy on VAS scores at 5–7 days time-point meta-analysis; Figure S7: Sensitivity analysis excluding imputed results from Aksoy 2002 and Desai 2011 from the thiocolchicoside efficacy on VAS scores at 5–7 days time-point meta-analysis; Table S1: Detailed search strategy for each database; Table S2: List of reports excluded after the full-text screening process and reasons of exclusion; Table S3: Inclusion characteristics of patients with low back pain within the included studies; Table S4: Frequency of adverse events in the included studies.
Tipo:
File Supplementare
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
244.67 kB
Formato
Zip File
|
244.67 kB | Zip File | Visualizza/Apri |
jcm-13-06133.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
2.19 MB
Formato
Adobe PDF
|
2.19 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.